GE HealthCare + CMDC
GE HealthCare
Chicago, Illinois · 2 relationships
Active relationship
Joint Venture · 2023–present
CMDC
Beijing, Beijing · 1 relationship
Analysis
In February 2023, GE HealthCare China and China National Medical Device Co., Ltd. (CMDC), a Sinopharm subsidiary, agreed to form a long-term joint venture for China's medical-imaging market. GE HealthCare's filing says the venture would develop, manufacture and commercialize equipment in China, with CMDC holding the majority stake and the transaction subject to regulatory approvals. [1]
The initial product brief was deliberately focused. The companies said the venture would start with non-premium computed tomography and general-imaging ultrasound systems intended for primary-care and rural settings, while leaving open the possibility of expanding the product scope later. That positioning links the venture to localization and broader access rather than only to GE HealthCare's premium hospital segment. [1]
The partnership became a market-facing business in November 2023, when Sinopharm announced the joint launch of the SINO IMAGING brand at the China International Supply Chain Expo. Sinopharm's launch materials describe CT and ultrasound as the initial categories and say the roadmap could extend to MRI, intelligent-assisted diagnosis and other medical devices as the brand develops. [2] [3]
Sinopharm's 2023 annual report treats the venture and the brand release as the group's entry into medical-imaging equipment manufacturing and places the initiative within a broader localization strategy. The sources reviewed document the formation, ownership direction, initial products and public launch, but do not provide a later audited revenue figure, installed-base count or a complete disclosure of the venture's legal operating footprint. [4] [1]
Participants
Continue through either entity
Chicago, Illinois · 2 records in this database
GE HealthCare Technologies Inc. is a standalone healthcare-technology company that provides medical technology, pharmaceutical diagnostics, and AI, cloud, and software solutions. Its investor materials describe a business serving patients and providers for 130 years, with approximately 54,000 colleagues, customers in more than 160 countries, 2025 revenue of $20.6 billion, and an installed base of about five million units. [1] GE HealthCare completed its separation from General Electric effective January 3, 2023 and began trading independently on Nasdaq under the ticker GEHC on January 4. [2]
The company organizes its current offering across Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions. [1] Its imaging activities include molecular imaging, computed tomography, magnetic resonance, women’s health, and X-ray, while its advanced-visualization activities include specialized ultrasound and procedural guidance. [3] Patient Care Solutions includes monitoring and life-support solutions, and Pharmaceutical Diagnostics supplies imaging agents used in diagnostic procedures. [1] [3] GE HealthCare’s precision-care strategy combines imaging, clinical data connectivity, and artificial intelligence to support diagnosis and treatment decisions. [2]
GE HealthCare traces its technical heritage to early medical-imaging work and describes a 125-year innovation legacy that began with some of the earliest X-ray breakthroughs and now extends to AI-enabled devices and connected care. [4] The company’s historical account presents the evolution as a progression from X-ray equipment toward systems that combine images with information about physiology, molecular activity, and treatment response. [4] The 2023 transaction made healthcare a separately governed public company alongside GE’s aviation and energy successors, so GE HealthCare should be treated as its own corporate entity in this database. [2]
Beijing, Beijing · 1 record in this database
China National Medical Device Co., Ltd. (CMDC) is identified by Sinopharm as the business carrier for medical-equipment development under China National Pharmaceutical Group and Sinopharm Group. [1] [2] Sinopharm’s group profile places CMDC alongside China National Scientific Instruments and Materials as a core platform in its medical-equipment manufacturing strategy. [1] [2]
CMDC’s own group description emphasizes a medical-equipment distribution network and comprehensive medical-device services rather than a single device product. [2] It says the company has launched the FLI+SPD 3.0 intelligent-upgrade solution, is building a digital supply-chain platform and has developed research-management capabilities; it also describes CMDC as one of the first demonstration units for comprehensive use of unique-device-identification (UDI) systems. [2]
The company operates within a wider Sinopharm healthcare and supply-chain ecosystem. [1] Sinopharm says its pharmaceutical logistics business serves more than 700,000 end customers, including primary, secondary and tertiary hospitals, retail pharmacies, distributors and grassroots medical institutions. [1] That parent-group figure is not a CMDC-only customer count, but it helps describe the distribution infrastructure surrounding the medical-device platform. [1]
CMDC’s relevance to international technology partnerships is illustrated by its February 2023 agreement with GE Healthcare China. [3] The parties announced a Chinese joint venture for research, development and manufacturing of high-end medical-imaging equipment, with CMDC holding the majority stake; Sinopharm characterized the project as a way to combine the parties’ capabilities and accelerate domestic registration, market launch and production of imaging equipment. [3]